Principal Investigator
An internationally known opinion leader in type 2 diabetes, Dr. Rosenstock is Senior Scientific Advisor for Velocity Clinical Research, Director of Velocity’s site at Medical City Dallas, and Clinical Professor of Medicine at the University of Texas Southwestern Medical Center, Dallas. Dr. Rosenstock has long focused on exploring novel agents and therapeutic strategies for glycemic control, and particularly early combination therapies for type 2 diabetes.
Over the last 30 years, he has participated in hundreds of clinical trials and has had an active role in the development of new oral agents, incretin-related therapies, and insulin preparations, often acting as a lead clinical investigator and scientific advisor on the design and reporting of clinical trials on novel diabetes drugs. Dr. Rosenstock has been the author or co-author of 375 peer-reviewed manuscripts (h-index 123) and hundreds of scientific abstracts. He is considered a key opinion leader in type 2 diabetes.